Simplify Logo

Full-Time

R&D Molecular Associate

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Healthcare
Biotechnology

Junior, Mid

Chicago, IL, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Bachelor’s degree with 2+ years experience in a molecular lab or completion of an advanced technical certificate program with a strong molecular lab component
  • Highly organized and systematic, superb attention to detail and ability to complete tasks with a high degree of accuracy
  • Proven ability to learn new skills quickly and adapt to new processes smoothly
  • Hands-on experience with any of the following molecular methods is highly desired: NGS library preparation methods, PCR methods such as: PCR, qPCR, RT-PCR, ddPCR, MLPA, Sanger Sequencing, Nucleic acid ligations, Nucleic acid analysis such as: quantitation by absorbance/fluorescence, gel & capillary electrophoresis, Magnetic bead-based DNA/RNA purification and size selection, DNA hybridization arrays
Responsibilities
  • Under the guidance of senior scientific staff, support the development of cutting-edge molecular assays for our high-throughput CAP/ CLIA/ NYSDOH accredited clinical lab
  • Assist in troubleshooting and quality control initiatives
  • Assist with development of automated processes
  • Execute molecular protocols with a high degree of precision and attention to detail
  • Generate detailed documentation of experimental execution
  • Process clinical samples through wet lab workflows

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Stage

Series G

Total Funding

$1.3B

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

4%

1 year growth

12%

2 year growth

35%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
  • Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
  • The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.

What critics are saying

  • The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
  • Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.

What makes Tempus unique

  • Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
  • Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
  • Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.